Scientific work

Doç. Dr. Senem Maral

152 publications. The source of the information is stated next to each publication.

Back to profile

  1. Universal Use of Novel Oral Anticoagulant Prophylaxis in Myeloma Patients Undergoing IMiD-Based Therapy: Real-World Experience

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020453 PMID 41598391 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  2. Real-World Experience with Belinostat in the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

    Annals of Medical Research, 2026

    DOI 10.5455/annalsmedres.2025.07.193 Open-access full textSource: OpenAlex

  3. A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15145401 PMID 42513315 Open-access full textSource: OpenAlex

  4. Enterovirus Encephalitis Developing After Treatment for Follicular Lymphoma: A Case Report

    SN Comprehensive Clinical Medicine, 2026

    DOI 10.1007/s42399-026-02560-z Source: OpenAlex

  5. Real-World Effectiveness and Renal Safety of Foscarnet for CMV Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166365 PMID 42652768 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  6. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

    New England Journal of Medicine, 2026

    DOI 10.1056/nejmoa2603870 PMID 42212933 7 citations (Europe PMC) Source: OpenAlex

  7. Talquetamab–Daratumumab in Relapsed or Refractory Myeloma

    New England Journal of Medicine, 2026

    DOI 10.1056/nejmoa2604657 PMID 42294841 8 citations (Europe PMC) Source: OpenAlex

  8. MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.7507 Source: OpenAlex

  9. POSTER: MM-593: Phase 3 Randomized Study of Talquetamab + Daratumumab ± Pomalidomide vs Daratumumab + Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)01331-5 Source: OpenAlex

  10. MM-593: Phase 3 Randomized Study of Talquetamab + Daratumumab ± Pomalidomide vs Daratumumab + Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)02897-1 Source: OpenAlex

  11. PA-350 Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (D) ± Pomalidomide (P) vs D Plus P and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)03713-4 Source: OpenAlex

  12. PHASE 3, RANDOMIZED STUDY OF TALQUETAMAB (TAL) PLUS DARATUMUMAB (DARA) ± POMALIDOMIDE (POM) VS DARA PLUS POM AND DEXAMETHASONE (DPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): MONUMENTAL-3

    Hematology Transfusion and Cell Therapy, 2026

    DOI 10.1016/j.htct.2026.107913 Source: OpenAlex

  13. MAJESTEC-9: A PHASE 3 RANDOMIZED STUDY OF TECLISTAMAB MONOTHERAPY VS INVESTIGATOR’S CHOICE OF POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE OR CARFILZOMIB AND DEXAMETHASONE (PVD/KD) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

    Hematology Transfusion and Cell Therapy, 2026

    DOI 10.1016/j.htct.2026.107889 Source: OpenAlex

  14. A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient

    Annals of Hematology, 2025

    DOI 10.1007/s00277-024-06118-8 PMID 39847114 1 citation (Europe PMC) Source: OpenAlex

  15. When high dose methotrexate stops working, a successful bridge to transplant with TEDDI-R in a case of secondary CNS lymphoma

    Annals of Hematology, 2025

    DOI 10.1007/s00277-025-06285-2 PMID 40016397 Open-access full textSource: OpenAlex

  16. Myth or reality: Graft versus host disease after autologous hematopoietic cell transplantation, a multicentre experience

    Transplant Immunology, 2025

    DOI 10.1016/j.trim.2025.102286 PMID 40907722 Source: OpenAlex

  17. Successful treatment of steroid-refractory gastrointestinal GVHD with ruxolitinib in a patient after autologous stem cell transplantation: a case report

    International Journal of Hematology, 2025

    DOI 10.1007/s12185-025-04073-2 PMID 41004031 Source: OpenAlex

  18. Cutaneous cytomegalovirus infection: a case report

    Skin Health and Disease, 2025

    DOI 10.1093/skinhd/vzaf057 PMID 42222707 Open-access full textSource: OpenAlex

  19. Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14207367 PMID 41156238 Open-access full textSource: OpenAlex

  20. The Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous Solid Tumor History

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/j.clml.2025.10.006 PMID 41206323 Source: OpenAlex

  21. Liposomal Amphotericin B-Induced Distal Renal Tubular Acidosis in a Patient with T-ALL and Febrile Neutropenia: A Diagnostic Challenge

    Research Square, 2025

    DOI 10.21203/rs.3.rs-6533569/v1 Open-access full textSource: OpenAlex

  22. AML-556: Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)01691-x Source: OpenAlex

  23. POSTER: AML-556 Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)00540-3 Source: OpenAlex

  24. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience

    Leukemia Research, 2024

    DOI 10.1016/j.leukres.2024.107495 PMID 38599153 3 citations (Europe PMC) Source: OpenAlex

  25. Atypical presentation of PJP: hypercalcemia and kidney injury in an allogeneic stem cell transplant recipient

    BMC Infectious Diseases, 2024

    DOI 10.1186/s12879-024-10074-z PMID 39448907 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  26. Original vs. Generic Plerixafor for the Mobilization of Stem Cells in Multiple Myeloma Patients

    Indian Journal of Hematology and Blood Transfusion, 2024

    DOI 10.1007/s12288-024-01841-8 PMID 39917490 Open-access full textSource: OpenAlex

  27. Azacitidine-related pyoderma gangrenosum

    Annales de Dermatologie et de Vénéréologie, 2024

    DOI 10.1016/j.annder.2024.103323 PMID 39488194 Source: OpenAlex

  28. Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis

    Turkish Journal of Hematology, 2024

    DOI 10.4274/tjh.galenos.2024.2023.0450 PMID 39501735 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  29. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

    Frontiers in Immunology, 2023

    DOI 10.3389/fimmu.2023.1276295 PMID 37901215 18 citations (Europe PMC) Open-access full textSource: OpenAlex

  30. Prospective Real-World Outcomes of Acute Myeloid Leukemia

    Blood, 2023

    DOI 10.1182/blood-2023-182800 Open-access full textSource: OpenAlex

  31. The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients

    AYBU AVESIS, 2023

    DOI 10.4999/uhod.236829 Source: OpenAlex

  32. Castleman Disease: A Multicenter Case Series from Turkey

    Turkish Journal of Hematology, 2022

    DOI 10.4274/tjh.galenos.2022.2021.0670 PMID 35176839 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  33. Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience

    Journal of Hematopathology, 2022

    DOI 10.1007/s12308-022-00488-6 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  34. A rare case of pulmonary lymphomatoid granulomatosis complicated with venous thrombosis.

    Sarcoidosis vasculitis and diffuse lung diseases, 2022

    DOI 10.36141/svdld.v38i4.10140 PMID 35115745 Open-access full textSource: OpenAlex

  35. Marjinal Zon Lenfoma Tanılı Hastalarda Klinik Özellikler ve Olası Prognostik Faktörler: İki Merkezden Retrospektif Analiz

    LLM Dergi, 2022

    DOI 10.5578/llm.20229903 Open-access full textSource: OpenAlex

  36. The impact of hematological parameters on survival for patients with COVID-19

    Ahi Evran Medical Journal, 2022

    DOI 10.46332/aemj.1014259 Open-access full textSource: OpenAlex

  37. Analysis of Demographic and Disease Characteristics of Patients with Chronic Myeloid Leukemia: A Single Centre Retrospective Analysis

    Acta Oncologica Turcica, 2022

    DOI 10.5505/aot.2022.08831 Open-access full textSource: OpenAlex

  38. Does blood type have an effect on the course of COVID-19?

    Sağlık Akademisi Kastamonu, 2022

    DOI 10.25279/sak.1014330 Open-access full textSource: OpenAlex

  39. Single Centre Experience: Bening and Malign Hematological Patients with COVID-19

    Sağlık Akademisi Kastamonu, 2022

    DOI 10.25279/sak.1061701 Open-access full textSource: OpenAlex

  40. Multiple Myeloma ve Plazma Hücreli Neoplaziler

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1210 Source: OpenAlex

  41. Hematolojide Güncel Yaklaşımlar

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1547 Open-access full textSource: OpenAlex

  42. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

    Turkish Journal of Hematology, 2021

    DOI 10.4274/tjh.galenos.2021.2021.0287 PMID 34521187 7 citations (Europe PMC) Open-access full textSource: OpenAlex

  43. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

    Clinical Lymphoma Myeloma & Leukemia, 2021

    DOI 10.1016/j.clml.2021.04.004 PMID 34059487 9 citations (Europe PMC) Open-access full textSource: OpenAlex

  44. The outcome of COVID-19 in patients with hematological malignancy

    memo - Magazine of European Medical Oncology, 2021

    DOI 10.1007/s12254-021-00775-5 PMID 34904019 7 citations (Europe PMC) Open-access full textSource: OpenAlex

  45. Hypercalcemia associated with the interaction between all trans retinoic acid and posaconazole in an acute promyelocytic leukemia case

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211007889 PMID 33847196 6 citations (Europe PMC) Source: OpenAlex

  46. Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211060730 PMID 34775854 3 citations (Europe PMC) Source: OpenAlex

  47. RECURRENT AUTOIMMUNE HEMOLYTIC ANEMIA AFTER MRNA COVID-19 VACCINE (PFIZER-BIONTECH)

    Hematology Transfusion and Cell Therapy, 2021

    DOI 10.1016/j.htct.2021.10.1057 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  48. A RARE CASE: POSTTRANSPLANT NK/T CELL LYMPHOMA

    Hematology Transfusion and Cell Therapy, 2021

    DOI 10.1016/j.htct.2021.10.1033 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  49. CASE REPORT: FOLLICULAR LYMPHOMA PRESENTED WITH CHYLOTHORAX

    Hematology Transfusion and Cell Therapy, 2021

    DOI 10.1016/j.htct.2021.10.1039 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  50. The Prognostic Value of Blood Count Parameters in Patients with Diffuse Large B Cell Lymphoma

    Akdeniz Medical Journal, 2021

    DOI 10.17954/amj.2021.2566 1 citation (OpenAlex) Open-access full textSource: OpenAlex